SBIR-STTR Award

Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenic requiring use of an immunological adjuvant for best effect Adjuvance s semi synthetic saponin adjuvant Titer Quil TQL has shown remarkable efficacy with a variety of antigens with no detectable reactogenicity When combined with of the leading vaccines against influenza Fluzone Fluarix and Flublok striking augmentation of the antibody response against the A H N hemagglutinin HA antigen and more than fold vaccine dose saving was seen with all vaccines but this was most striking with the most defined and least immunogenic vaccine Flublok The objectives of this Phase proposal are to determine if this augmentation applies to the other antigens in Flu vaccines A H N and B to determine if it applies to the T cell responses to conduct an IND enabling stability study of Flublok and to determine whether mixture of TQL and Flublok with additional immunological adjuvants further augments the serologic or especially T cell response to the HA antigen. Successful completion of this study will support initiation of IND enabling studies in a Phase SBIR application for Flublok plus TQL and use of TiterQuil with other types of vaccines